StreetInsider.com News Articles

Form 25-NSE TEVA PHARMACEUTICAL INDU Filed by: NEW YORK STOCK EXCHANGE LLC

Mon, 14 Sep 2026 14:32:00 -0400

si-local-file:///var/storage/secattach/20260914/27057917.html

Form 424B5 TEVA PHARMACEUTICAL INDU

Fri, 11 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260911/27053604.html

Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 09

Fri, 11 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260911/27052916.html

Teva prices $4.9B senior notes offering to refinance debt

Thu, 10 Sep 2026 06:05:18 -0400

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has priced an offering of approximately $4.9 billion in senior notes, according to a company statement. Settlement is expected on or about Sept. 16, 2026, subject to customary closing conditions.

The offering consists of five tranches issued through Teva subsidiaries: €1 billion of 4.250% euro-denominated notes due 2033; €500 million of 4.625% euro-denominated notes due 2036; $1 billion of 5.500% dollar-denominated notes due 2034; $1 billion of 5.750% dollar-denominated notes due 2037; and $1.2 billion of 5.250% dollar-denominated notes due 2032.

Teva said it plans to use the net proceeds, along with cash on hand, primarily

Teva prices $4.9B senior notes offering to refinance debt

Thu, 10 Sep 2026 06:05:18 -0400

Teva said it plans to use the net proceeds, along with cash on hand, primarily

Form FWP TEVA PHARMACEUTICAL INDU Filed by: TEVA PHARMACEUTICAL INDUSTRIES LTD

Thu, 10 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260910/27044679.html

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Thu, 10 Sep 2026 06:04:00 -0400

TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the “Conditional Redemptions”), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, for general corporate purposes, including the repayment of outstanding debt upon

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Thu, 10 Sep 2026 06:04:00 -0400

Form FWP TEVA PHARMACEUTICAL INDU Filed by: TEVA PHARMACEUTICAL INDUSTRIES LTD

Thu, 10 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260910/27044666.html

Leerink Starts Teva Pharma (TEVA) at Outperform

Wed, 09 Sep 2026 06:21:14 -0400

Leerink analyst Daniel Clark initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $45.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $36.76 yesterday.

Form 424B5 TEVA PHARMACEUTICAL INDU

Tue, 08 Sep 2026 06:55:00 -0400

si-local-file:///var/storage/secattach/20260908/27032900.html

Teva Pharma (TEVA) PT Raised to $48 at UBS

Mon, 07 Sep 2026 05:26:57 -0400

UBS analyst Ashwani Verma raised the price target on Teva Pharma (NYSE: TEVA) to $48.00 (from $42.00) while maintaining a Buy rating.

Teva plans senior notes offering to refinance existing debt

Mon, 07 Sep 2026 03:53:23 -0400

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced plans to issue senior notes through special purpose finance subsidiaries, according to a press release dated Sept. 7, 2026.

Two tranches are planned: EUR-denominated senior notes through Teva Pharmaceutical Finance Netherlands II B.V., and USD-denominated senior notes through Teva Pharmaceutical Finance Netherlands III B.V. and Teva Pharmaceutical Finance Netherlands IV B.V. The offering is subject to market conditions.

Teva said it intends to use the net proceeds, along with cash on hand, primarily to fund conditional redemptions of several existing note series. The targeted redemptions include all outstanding 6.750% Senior Notes due 2028,

Teva Announces Launch of Offering of Senior Notes

Mon, 07 Sep 2026 03:53:00 -0400

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”) intend to offer USD-denominated Senior Notes (the “USD Notes” and, together with the Euro Notes, the “Notes”).

Teva Announces Launch of Offering of Senior Notes

Mon, 07 Sep 2026 03:53:00 -0400

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Fri, 04 Sep 2026 11:30:00 -0400

TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With this upgrade, along with the other recent upgrades from Fitch and Moody’s, Teva now has investment-grade credit ratings from all the agencies which cover its debt.

Eli Kalif, Teva's Chief Financial Officer, commented: “Teva’s trio of rating upgrades in just a few months reflects the strong execution of our Pivot to Growth strategy

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Fri, 04 Sep 2026 11:30:00 -0400

TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With this upgrade, along with the other recent upgrades from Fitch and Moody’s, Teva now has investment-grade credit ratings from all the agencies which cover its debt.

Eli Kalif, Teva's Chief Financial Officer, commented: “Teva’s trio of rating upgrades in just a few months reflects the strong execution of our Pivot to Growth strategy

Teva Pharma (TEVA) PT Raised to $48 at UBS

Fri, 04 Sep 2026 05:46:18 -0400

UBS analyst Ashwani Verma raised the price target on Teva Pharma (NYSE: TEVA) to $48.00 (from $42.00) while maintaining a Buy rating.
The analyst comments "We see TEVA's Ph2 success in Celiac as an important milestone, depicting the company can build out a high-science, quality R&D pipeline via internal development. Considering Teva has historically been a generics company, we see this type of impressive R&D asset (among many others) as a key reason the stock warrants a significant premium to current multiple. The immediate stock reaction to positive Ph2 Celiac data has been underwhelming in our view, but this creates meaningful

Teva Pharma (TEVA) PT Raised to $48 at UBS

Fri, 04 Sep 2026 05:46:18 -0400

UBS analyst Ashwani Verma raised the price target on Teva Pharma (NYSE: TEVA) to $48.00 (from $42.00) while maintaining a Buy rating.
The analyst comments "We see TEVA's Ph2 success in Celiac as an important milestone, depicting the company can build out a high-science, quality R&D pipeline via internal development. Considering Teva has historically been a generics company, we see this type of impressive R&D asset (among many others) as a key reason the stock warrants a significant premium to current multiple. The immediate stock reaction to positive Ph2 Celiac data has been underwhelming in our view, but this creates meaningful

Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 03

Thu, 03 Sep 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260903/27025145.html

Form 8-K TEVA PHARMACEUTICAL INDU For: Aug 31

Thu, 03 Sep 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260903/27024999.html

Teva's TEV '408 meets primary endpoint in celiac disease trial

Wed, 02 Sep 2026 07:08:42 -0400

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced positive topline results from an ongoing Phase 2a study of TEV '408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease.
The study met its primary endpoint, showing statistically significant prevention of gluten-induced intestinal damage compared to placebo at week 8. The trial enrolled 50 adult participants already following a gluten-free diet with minimal intestinal damage at baseline. Participants received a single subcutaneous dose of TEV '408 two weeks before beginning a six-week daily gluten challenge.
The primary endpoint, measured by the villous height-to-crypt depth ratio, showed a least squares mean change

Teva's TEV '408 meets primary endpoint in celiac disease trial

Wed, 02 Sep 2026 07:08:42 -0400

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced positive topline results from an ongoing Phase 2a study of TEV '408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease.
The study met its primary endpoint, showing statistically significant prevention of gluten-induced intestinal damage compared to placebo at week 8. The trial enrolled 50 adult participants already following a gluten-free diet with minimal intestinal damage at baseline. Participants received a single subcutaneous dose of TEV '408 two weeks before beginning a six-week daily gluten challenge.
The primary endpoint, measured by the villous height-to-crypt depth ratio, showed a least squares mean change

Teva in talks with Trump administration on Medicaid drug pricing

Mon, 31 Aug 2026 16:08:02 -0400

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced it is in active discussions with the Trump administration to reach an agreement aimed at lowering the cost of select medicines for American patients covered by Medicaid.
According to a press release, the proposed deal would align U.S. Medicaid pricing for certain medicines with pricing in other developed markets through what Teva calls the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework. The agreement would also include a Most-Favored-Nation pricing commitment for applicable future innovative product launches.
Teva said it has also offered a dedicated reserve of certain active pharmaceutical ingredients (API) to

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Mon, 31 Aug 2026 16:06:00 -0400

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities.
 
“Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow,” said Chris Fox, President, Teva USA. “Teva built its